Calidi Biotherapeutics, Inc.
CLDI NYSE
SEC CIK 1855485
Follow Calidi Biotherapeutics
Weekly email: filings, results
Net income
−$3.6M
+29.2% vs same quarter last year
EPS, diluted
−$1.47
Operating cash flow
−$2.3M
+44.8% vs same quarter last year
Operating income
−$4.3M
+13.9% vs same quarter last year
Source: SEC XBRL filings · latest filing
Show the numbers
| Year | Net income |
|---|---|
| FY25 | −$19.9M |
| FY24 | −$22.1M |
| FY23 | −$29.2M |
| FY22 | - |
| FY21 | - |